NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/07/2026
Back to search
Official data from USPTO
EXTENDED BENCH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
EXTENDED BENCH
ST13
US500000099322680Class
1, 5, 40, 42
Filing
99322680
Registration
8331134
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
07/07/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
08/06/2025
Registration date
07/07/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/07/2026
Last transaction
07/07/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
24
Owner location
Northumberland, GB
Examiner
NEPTUNE, EVONNE MARIE
Law office
N90
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Sterling Pharma Solutions Limited
Representatives
Laura A. Kees Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in the pharmaceutical industry; active chemical ingredients for use in the manufacture of pharmaceuticals
Class 5
Pharmaceuticalspsychotropicsantihelminticsanti-infectiveslipid lowering agentsinducers of erectionsinduction agentsneuromuscular blocking agentssedativesanti-cancer medicationanti-inflammatoriesanti-fungalsanti-bacterialsanti-spasmodicsappetite stimulantsbronchodilatorsappetite suppressantsanti-convulsivesneuroprotective drugsanti-anxiety medicationanti-depressantsanti-ischemicsanti-psychotics; pharmaceutical preparations for treating diabetesearnose and throat disordersepilepsygenetic disordershematological disordershormonal disordersinfectious diseaseslymphomametabolic disordersmouth and dental disordersmusculoskeletal disordernon-malignant disordernutritional disorderspainrare ophthalmological diseasesrare cancersrare infectious diseasesrare genetic diseasesrare respiratory diseasesrare central nervous system diseasesrare gastrointestinal diseasesrare immunological diseasesrare cardiovascular diseasesrare dermatological diseasesrare urinary system and sex hormone diseasesrare womens health diseasesrare earnosethroat diseases; pharmaceuticals for medical or veterinary purposespharmaceutical preparations and substances for the treatment of viralinfectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; vaccines; medicine for treating diabetesearnose and throat disordersepilepsygenetic disordershematological disordershormonal disordersinfectious diseaseslymphomametabolic disordersmouth and dental disordersmusculoskeletal disordernon-malignant disordernutritional disorderspainrare ophthalmological diseasesrare cancersrare infectious diseasesrare genetic diseasesrare respiratory diseasesrare central nervous system diseasesrare gastrointestinal diseasesrare immunological diseasesrare cardiovascular diseasesrare dermatological diseasesrare urinary system and sex hormone diseasesrare womens health diseasesrare earnosethroat diseases
Class 40
Custom manufacturing in the field of pharmaceuticals; processing of pharmaceuticals; custom manufacture of pharmaceuticals; treatment of pharmaceuticals; treatment and disposal being destruction of pharmaceutical waste; informationadvice and consultancy services in relation to the aforesaid services
Class 42
Pharmaceutical research services; pharmaceutical development services; pharmaceutical product design services; testing of pharmaceuticals; scientific research in the nature of conducting clinical trials for others relating to pharmaceuticals and chemicals; pharmaceutical analysischemical composition analysistestinganalysisevaluation of pharmaceuticals of others to determine conformity with certification standards; pharmaceutical laboratory research services relating to pharmaceuticals; pharmaceutical product evaluation; pharmaceutical reportspreparation of reports relating to pharmaceutical research; inspection of pharmaceuticals; biological research services; quality control and authentication services for others in the field of pharmaceuticals; informationadvice and consultancy services in relation to the aforesaid services
Publications
History of USPTO decisions and trademark events.
26 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/07/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/19/2026
PUBO
PUBLISHED FOR OPPOSITION
05/19/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/13/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/24/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
04/24/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/24/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
04/24/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/24/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/09/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/09/2026
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/09/2026
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/23/2026
GNFR
FINAL REFUSAL E-MAILED
03/23/2026
CNFR
FINAL REFUSAL WRITTEN
03/23/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/17/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/17/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/17/2026
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/19/2025
GNRT
NON-FINAL ACTION E-MAILED
12/19/2025
CNRT
NON-FINAL ACTION WRITTEN
12/19/2025
DOCK
ASSIGNED TO EXAMINER
12/19/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/06/2025
MAFR
APPLICATION FILING RECEIPT MAILED
08/06/2025
NWAP
NEW APPLICATION ENTERED
08/06/2025
Continuous trademark protection
Get notified about every new filing that threatens EXTENDED BENCH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.